HERON THERAPEUTICS, INC. /DE/ (HRTX) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$0.36

From 52W high−75.20%

Volume1.54M

Market cap$70.15M

P/E (TTM)—

P/S (TTM)0.5x

Div yield—

Key dataOct 19, 2026

Open

$0.36

From 52W high

−75.20%

Volume

1.54M

Market cap

$70.15M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−6.3x

P/E (TTM)

—

RSI (14)

50.6

MomentumView details →

1D Return

+2.35%

YTD Return

−72.71%

SummaryUpdated Jun 1, 2026

Heron Therapeutics, Inc. (NASDAQ:HRTX) is a San Diego-based biotechnology company founded in 1983 that develops specialized treatments for unmet medical needs in oncology and acute care settings. Originally known as A.P. Pharma, Inc., the company rebranded to Heron Therapeutics in 2014 to reflect its focus on innovative drug delivery technologies. The company has evolved from a development-stage biotechnology firm to a commercial-stage pharmaceutical company with multiple approved products generating over $144 million in annual revenue as of 2024.

Ask drillr about HERON THERAPEUTICS, INC. /DE/ →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−6.3x

EV/Sales

1.2x

P/S (TTM)

0.5x

P/B (TTM)

10.2x

ProfitabilityView details →

Gross Margin

70.07%

Net Margin

−22.52%

EBITDA Margin

−18.53%

ROE (TTM)

−492.89%

ROA (TTM)

−13.50%

Asset Turnover

0.61x

GrowthView details →

Revenue YoY

+0.99%

EPS YoY

—

FCF YoY

+58.91%

Revenue CAGR 3Y

+12.89%

EPS CAGR 3Y

−34.68%

EBITDA YoY

—

MomentumView details →

1D Return

+2.35%

YTD Return

−72.71%

1Y Return

−73.72%

RSI (14)

50.6

vs 50D SMA

+7.30%

vs 200D SMA

−52.52%

Capital & dividendView details →

Debt/Equity

21.48x

Current Ratio

2.49x

Quick Ratio

1.51x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.03

EPS Surprise

−500.00%

Beats (12Q)

6/12

Next Q EPS Est

−$0.03

Avg Surprise (4Q)

−191.87%

Rev Surprise

−10.72%

Financials snapshotView financials →

Revenue (TTM)

151.18M

Net Income (TTM)

−34.05M

Op. CF (TTM)

−11.61M

Next earningsNov 3, 2026 →

Latest newsMore news →

Heron Therapeutics reported Q2 2026 total net revenue of $37.7 million, up 1.3% year-over-year, with a net loss of $5.5 million and diluted EPS of -$0.03.71d ago

Similar companies

MediciNova, Inc.MNOV Cognition Therapeutics, Inc.CGTX Cardiff Oncology, Inc.CRDF Telomir Pharmaceuticals, Inc. Common StockTELO Acrivon Therapeutics, Inc. Common StockACRV Nutriband Inc.NTRB Find similar companies →

Latest newsMore news →

Heron Therapeutics, Inc. signed a Development and License Agreement granting it an exclusive license to import, distribute, sell and market certain products in the United States and a non-exclusive worldwide manufacturing license, with Long Grove Pharmaceuticals, LLC and Capstone Development Services Company, LLC as counterparties.20d ago Heron Therapeutics reported Q2 2026 total net revenue of $37.7 million, up 1.3% year-over-year, with a net loss of $5.5 million and diluted EPS of -$0.03.71d ago